SXTC vs SBFM

For growth investors, Sunshine Biopharma, Inc.

(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, China SXT Pharmaceuticals, Inc.

(SXTC) delivered a total return of -100. 0%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: SXTC returned -100. 0% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), China SXT Pharmaceuticals, Inc.

(SXTC) is the lower-risk stock at 1. 16β versus Sunshine Biopharma, Inc. 's 1. 31β — meaning SBFM is approximately 13% more volatile than SXTC relative to the S&P 500. On balance sheet safety, Sunshine Biopharma, Inc. (SBFM) carries a lower debt/equity ratio of 4% versus 6% for China SXT Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sunshine Biopharma, Inc.

(SBFM) is pulling ahead at 44. 7% versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). On earnings-per-share growth, the picture is similar: Sunshine Biopharma, Inc. grew EPS 97. 9% year-over-year, compared to -129. 1% for China SXT Pharmaceuticals, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sunshine Biopharma, Inc.

(SBFM) is the more profitable company, earning -14. 7% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps -14. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBFM leads at -16. 7% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — SBFM leads at 30. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, China SXT Pharmaceuticals, Inc.

(SXTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16)). Both have compounded well over 10 years (SXTC: -100. 0%, SBFM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SXTC is a small-cap quality compounder stock; SBFM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.